Epitalon vs Rusfertide
Overview
Epitalon is primarily a anti-aging & longevity peptide, while Rusfertide is used for weight management & metabolic.
This page compares Epitalon and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Epitalon | Rusfertide | |
|---|---|---|
| Category | Anti-aging & Longevity | Weight Management & Metabolic |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 5-10 mg | 19-108 mg |
| Frequency | cycle | once weekly, subcutaneous |
| Reported benefits | Areas studied (research-reported, not established efficacy): telomerase activation and telomere elongation in human cell lines (PMID 12937682; DOI 10.1007/s10522-025-10315-x); increased melatonin synthesis and circadian effects in a small human study; lower overall and cardiovascular mortality in a 12-15 year single-lab trial that used pineal extract (epithalamin), not synthetic AEDG (PMID 17426848, 22451889). No independent multi-center RCTs; not FDA-approved. | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | Khavinson-group trials reported no serious adverse events (e.g., n=162 retinitis pigmentosa trial, PMID 12195242), but these are the only controlled safety data and remain unreplicated. Community use reports mild injection-site reactions. Theoretical concern: telomerase activation is a hallmark of most cancers, and a 2025 review (PMC11943447) notes carcinogenic potential is unstudied. No human pharmacokinetic or drug-interaction data. | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. Epitalon is categorised under Anti-aging & Longevity, while Rusfertide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Epitalon: not FDA-approved; compounding permitted with a prescription as of April 2026. Rusfertide: FDA-approved.
Dosing. Epitalon is typically dosed at 5-10 mg (cycle). Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking Epitalon and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Epitalon and Rusfertide?
- Epitalon is primarily a anti-aging & longevity peptide, while Rusfertide is used for weight management & metabolic. Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Rusfertide is FDA-approved for one or more indications.
- What is Epitalon used for?
- Longevity, telomere support.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take Epitalon and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking Epitalon and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Epitalon or Rusfertide FDA-approved?
- Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026). Rusfertide is FDA-approved for one or more indications.
Read the full articles
- Epitalon — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references